# Onconova Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onconova-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.onconova.com
- Total disclosed funding: $21M
- Latest round: Series F (May 29, 2007)
- Investors on record: 2

## About

Onconova Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapies for cancer treatment, leveraging novel drug discovery and development approaches.Onconova Therapeutics, Inc. specializes in oncology therapeutics and was founded in 1998. The company is headquartered in Newtown, Pennsylvania, USA. Steven Fruchtman leads the organization as CEO. Onconova has successfully raised a total of USD 21.00 mn through its most recent funding round, a Private Placement/Follow on that closed in September 2021. This funding supports the company’s ongoing research and operational efforts, highlighting its strategic focus on advancing cancer therapies.Onconova Therapeutics develops a range of innovative cancer treatment products designed to meet specific therapeutic needs. Their offerings include proprietary drug candidates aimed at various malignancies, focusing on improving patient outcomes. The company collaborates with healthcare providers and research institutions across North America, Europe, and Asia, ensuring their solutions address diverse clinical challenges in oncology.In the year 2022, Onconova Therapeutics reported a revenue of USD 226,000 and an EBITDA of USD -19,613,000, reflecting their early-stage operational status in the biotechnology sector.Onconova Therapeutics plans to utilize the USD 21.00 mn raised in September 2021 for working capital and general corporate purposes, allowing them to enhance their research and development efforts for new oncology products. The company aims to expand its reach into European and Asian markets by 2023, increasing availability and collaborations with international healthcare providers. Continued investment in clinical trials and the development of innovative therapies is central to their growth strategy.

## Funding rounds

- Series F, May 29, 2007, $13M — ICICI Venture
- Series E, Dec 22, 2005, $7.9M — Blackstone Group, ICICI Venture

## Investors

- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series E
- ICICI Venture (https://capitalatlas.ai/funds/icici-venture) — Series E, Series F